Annual report
3353.TEDINET S100VT82
Period2024-03-01 → 2025-02-28
Filed2025-05-23
StandardJapan GAAP
ConsolidatedYes
Data checks22 of 22 passed
Key figures · 145
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥48.4bn | 2024-03-01 → 2025-02-28 | Cons. | Net sales |
| Revenue | ¥39.9bn | 2023-03-01 → 2024-02-29 | Cons. | Net sales |
| Revenue | ¥33.9bn | 2022-03-01 → 2023-02-28d | Cons. | Net sales (5-year summary) |
| Revenue | ¥33.6bn | 2021-03-01 → 2022-02-28d | Cons. | Net sales (5-year summary) |
| Revenue | ¥31.6bn | 2020-03-01 → 2021-02-28d | Cons. | Net sales (5-year summary) |
| Operating income | ¥1.7bn | 2024-03-01 → 2025-02-28 | Cons. | Operating income |
| Operating income | ¥1.6bn | 2023-03-01 → 2024-02-29 | Cons. | Operating income |
| Ordinary income | ¥1.8bn | 2024-03-01 → 2025-02-28 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2023-03-01 → 2024-02-29 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-03-01 → 2023-02-28d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.4bn | 2021-03-01 → 2022-02-28d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.2bn | 2020-03-01 → 2021-02-28d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.9bn | 2024-03-01 → 2025-02-28 | Cons. | Income before income taxes |
| Profit before tax | ¥1.7bn | 2023-03-01 → 2024-02-29 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.1bn | 2024-03-01 → 2025-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.0bn | 2023-03-01 → 2024-02-29 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥760m | 2022-03-01 → 2023-02-28d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥852m | 2021-03-01 → 2022-02-28d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥835m | 2020-03-01 → 2021-02-28d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.1bn | 2024-03-01 → 2025-02-28 | Cons. | Profit loss |
| Net income | ¥1.1bn | 2023-03-01 → 2024-02-29 | Cons. | Profit loss |
| Total assets | ¥34.2bn | at 2025-02-28 | Cons. | Assets |
| Total assets | ¥31.7bn | at 2024-02-29 | Cons. | Assets |
| Total assets | ¥27.5bn | at 2023-02-28d | Cons. | Total assets (5-year summary) |
| Total assets | ¥29.1bn | at 2022-02-28d | Cons. | Total assets (5-year summary) |
| Total assets | ¥28.6bn | at 2021-02-28d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥19.5bn | at 2025-02-28 | Cons. | Liabilities |
| Total liabilities | ¥17.8bn | at 2024-02-29 | Cons. | Liabilities |
| Net assets / equity | ¥14.7bn | at 2025-02-28 | Cons. | Net assets |
| Net assets / equity | ¥13.8bn | at 2024-02-29 | Cons. | Net assets |
| Net assets / equity | ¥12.6bn | at 2023-02-28d | Cons. | Net assets |
| Net assets / equity | ¥11.9bn | at 2022-02-28d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥10.5bn | at 2021-02-28d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥6.8bn | at 2025-02-28 | Cons. | Cash and deposits |
| Cash and deposits | ¥7.7bn | at 2024-02-29 | Cons. | Cash and deposits |
| Cash & equivalents | ¥6.6bn | at 2025-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.6bn | at 2024-02-29 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.3bn | at 2023-02-28d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.8bn | at 2022-02-28d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥6.8bn | at 2021-02-28d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.2bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.3bn | 2023-03-01 → 2024-02-29 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.3bn | 2022-03-01 → 2023-02-28d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.1bn | 2021-03-01 → 2022-02-28d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.8bn | 2020-03-01 → 2021-02-28d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.2bn | 2023-03-01 → 2024-02-29 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥478m | 2022-03-01 → 2023-02-28d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥216m | 2021-03-01 → 2022-02-28d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.2bn | 2020-03-01 → 2021-02-28d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥1.0bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥278m | 2023-03-01 → 2024-02-29 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.4bn | 2022-03-01 → 2023-02-28d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥65m | 2021-03-01 → 2022-02-28d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥591m | 2020-03-01 → 2021-02-28d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥301.35 | 2024-03-01 → 2025-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥276.7 | 2023-03-01 → 2024-02-29 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥202.2 | 2022-03-01 → 2023-02-28d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥226.92 | 2021-03-01 → 2022-02-28d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥221.31 | 2020-03-01 → 2021-02-28d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥3,747.7 | at 2025-02-28 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,523.25 | at 2024-02-29 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,207.14 | at 2023-02-28d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,030.61 | at 2022-02-28d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,791.36 | at 2021-02-28d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 41.2% | at 2025-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.8% | at 2024-02-29 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.8% | at 2023-02-28d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.1% | at 2022-02-28d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.7% | at 2021-02-28d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 8.3% | 2024-03-01 → 2025-02-28 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2023-03-01 → 2024-02-29 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.5% | 2022-03-01 → 2023-02-28d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2021-03-01 → 2022-02-28d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.1% | 2020-03-01 → 2021-02-28d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,547 | at 2025-02-28 | Cons. | Number of employees |
| Employees | 1,431 | at 2024-02-29 | Cons. | Number of employees |
| Employees | 1,297 | at 2023-02-28d | Cons. | Number of employees |
| Employees | 1,325 | at 2022-02-28d | Cons. | Number of employees |
| Employees | 1,304 | at 2021-02-28d | Cons. | Number of employees |
| Revenue | ¥1.3bn | 2024-03-01 → 2025-02-28 | Standalone | Operating revenue1 |
| Revenue | ¥1.1bn | 2023-03-01 → 2024-02-29 | Standalone | Operating revenue1 |
| Operating income | ¥620m | 2024-03-01 → 2025-02-28 | Standalone | Operating income |
| Operating income | ¥557m | 2023-03-01 → 2024-02-29 | Standalone | Operating income |
| Ordinary income | ¥680m | 2024-03-01 → 2025-02-28 | Standalone | Ordinary income |
| Ordinary income | ¥616m | 2023-03-01 → 2024-02-29 | Standalone | Ordinary income |
| Ordinary income | ¥592m | 2022-03-01 → 2023-02-28d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥432m | 2021-03-01 → 2022-02-28d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥319m | 2020-03-01 → 2021-02-28d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥752m | 2024-03-01 → 2025-02-28 | Standalone | Income before income taxes |
| Profit before tax | ¥551m | 2023-03-01 → 2024-02-29 | Standalone | Income before income taxes |
| Net income | ¥616m | 2024-03-01 → 2025-02-28 | Standalone | Profit loss |
| Net income | ¥457m | 2023-03-01 → 2024-02-29 | Standalone | Profit loss |
| Net income | ¥526m | 2022-03-01 → 2023-02-28d | Standalone | Net income loss (5-year summary) |
| Net income | ¥397m | 2021-03-01 → 2022-02-28d | Standalone | Net income loss (5-year summary) |
| Net income | ¥355m | 2020-03-01 → 2021-02-28d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥13.1bn | at 2025-02-28 | Standalone | Assets |
| Total assets | ¥12.7bn | at 2024-02-29 | Standalone | Assets |
| Total assets | ¥11.8bn | at 2023-02-28d | Standalone | Total assets (5-year summary) |
| Total assets | ¥12.5bn | at 2022-02-28d | Standalone | Total assets (5-year summary) |
| Total assets | ¥12.5bn | at 2021-02-28d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.7bn | at 2025-02-28 | Standalone | Liabilities |
| Total liabilities | ¥3.7bn | at 2024-02-29 | Standalone | Liabilities |
| Net assets / equity | ¥9.4bn | at 2025-02-28 | Standalone | Net assets |
| Net assets / equity | ¥9.0bn | at 2024-02-29 | Standalone | Net assets |
| Net assets / equity | ¥8.6bn | at 2023-02-28d | Standalone | Net assets |
| Net assets / equity | ¥8.3bn | at 2022-02-28d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥8.0bn | at 2021-02-28d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.2bn | at 2025-02-28 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.9bn | at 2024-02-29 | Standalone | Cash and deposits |
| EPS (basic) | ¥163.72 | 2024-03-01 → 2025-02-28 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥121.61 | 2023-03-01 → 2024-02-29 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥140.07 | 2022-03-01 → 2023-02-28d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥105.69 | 2021-03-01 → 2022-02-28d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥94.22 | 2020-03-01 → 2021-02-28d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥65 | 2024-03-01 → 2025-02-28 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥45 | 2023-03-01 → 2024-02-29 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2022-03-01 → 2023-02-28d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2021-03-01 → 2022-02-28d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥80 | 2020-03-01 → 2021-02-28d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,498.76 | at 2025-02-28 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,385.18 | at 2024-02-29 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,293.7 | at 2023-02-28d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,196.84 | at 2022-02-28d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,131.98 | at 2021-02-28d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 72.0% | at 2025-02-28 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.8% | at 2024-02-29 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.2% | at 2023-02-28d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.3% | at 2022-02-28d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.3% | at 2021-02-28d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 6.7% | 2024-03-01 → 2025-02-28 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.2% | 2023-03-01 → 2024-02-29 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.2% | 2022-03-01 → 2023-02-28d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.9% | 2021-03-01 → 2022-02-28d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.4% | 2020-03-01 → 2021-02-28d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 4,070,000 | at 2025-02-28 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,070,000 | at 2024-02-29 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,070,000 | at 2023-02-28d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,070,000 | at 2022-02-28d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,035,000 | at 2021-02-28d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 30 | at 2025-02-28 | Standalone | Number of employees |
| Employees | 22 | at 2024-02-29 | Standalone | Number of employees |
| Employees | 25 | at 2023-02-28d | Standalone | Number of employees |
| Employees | 25 | at 2022-02-28d | Standalone | Number of employees |
| Employees | 25 | at 2021-02-28d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 86
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-03-01 → 2025-02-28 | ¥61m |
| Reconciling Itemsreconciling | depreciation | 2024-03-01 → 2025-02-28 | ¥36m |
| Reconciling Itemsreconciling | revenue | 2024-03-01 → 2025-02-28 | −¥846m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-03-01 → 2025-02-28 | −¥846m |
| Reconciling Itemsreconciling | segment assets | at 2025-02-28 | ¥9.2bn |
| Reconciling Itemsreconciling | segment profit | 2024-03-01 → 2025-02-28 | −¥188m |
| Dispensing Pharmacyreportable segment | capex | 2024-03-01 → 2025-02-28 | ¥200m |
| Dispensing Pharmacyreportable segment | depreciation | 2024-03-01 → 2025-02-28 | ¥187m |
| Dispensing Pharmacyreportable segment | employees | at 2025-02-28 | 504 pure |
| Dispensing Pharmacyreportable segment | revenue | 2024-03-01 → 2025-02-28 | ¥24.7bn |
| Dispensing Pharmacyreportable segment | revenue external | 2024-03-01 → 2025-02-28 | ¥24.7bn |
| Dispensing Pharmacyreportable segment | segment assets | at 2025-02-28 | ¥7.5bn |
| Dispensing Pharmacyreportable segment | segment profit | 2024-03-01 → 2025-02-28 | ¥1.2bn |
| Health Carereportable segment | capex | 2024-03-01 → 2025-02-28 | ¥790m |
| Health Carereportable segment | depreciation | 2024-03-01 → 2025-02-28 | ¥349m |
| Health Carereportable segment | employees | at 2025-02-28 | 790 pure |
| Health Carereportable segment | revenue | 2024-03-01 → 2025-02-28 | ¥8.1bn |
| Health Carereportable segment | revenue external | 2024-03-01 → 2025-02-28 | ¥8.1bn |
| Health Carereportable segment | revenue intersegment | 2024-03-01 → 2025-02-28 | ¥600,000 |
| Health Carereportable segment | segment assets | at 2025-02-28 | ¥9.4bn |
| Health Carereportable segment | segment profit | 2024-03-01 → 2025-02-28 | ¥163m |
| Medical Products Wholesalereportable segment | capex | 2024-03-01 → 2025-02-28 | ¥23m |
| Medical Products Wholesalereportable segment | depreciation | 2024-03-01 → 2025-02-28 | ¥11m |
| Medical Products Wholesalereportable segment | employees | at 2025-02-28 | 224 pure |
| Medical Products Wholesalereportable segment | revenue | 2024-03-01 → 2025-02-28 | ¥16.2bn |
| Medical Products Wholesalereportable segment | revenue external | 2024-03-01 → 2025-02-28 | ¥15.4bn |
| Medical Products Wholesalereportable segment | revenue intersegment | 2024-03-01 → 2025-02-28 | ¥841m |
| Medical Products Wholesalereportable segment | segment assets | at 2025-02-28 | ¥6.1bn |
| Medical Products Wholesalereportable segment | segment profit | 2024-03-01 → 2025-02-28 | ¥345m |
| Real Estatereportable segment | depreciation | 2024-03-01 → 2025-02-28 | ¥42m |
| Real Estatereportable segment | employees | at 2025-02-28 | 1 pure |
| Real Estatereportable segment | revenue | 2024-03-01 → 2025-02-28 | ¥208m |
| Real Estatereportable segment | revenue external | 2024-03-01 → 2025-02-28 | ¥204m |
| Real Estatereportable segment | revenue intersegment | 2024-03-01 → 2025-02-28 | ¥5m |
| Real Estatereportable segment | segment assets | at 2025-02-28 | ¥2.1bn |
| Real Estatereportable segment | segment profit | 2024-03-01 → 2025-02-28 | ¥138m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-03-01 → 2025-02-28 | ¥1.0bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-03-01 → 2025-02-28 | ¥589m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-03-01 → 2025-02-28 | ¥49.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-03-01 → 2025-02-28 | ¥48.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-03-01 → 2025-02-28 | ¥846m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-02-28 | ¥25.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-03-01 → 2025-02-28 | ¥1.9bn |
| Reconciling Itemsreconciling | capex | 2023-03-01 → 2024-02-29 | ¥18m |
| Reconciling Itemsreconciling | depreciation | 2023-03-01 → 2024-02-29 | ¥32m |
| Reconciling Itemsreconciling | revenue | 2023-03-01 → 2024-02-29 | −¥879m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-03-01 → 2024-02-29 | −¥879m |
| Reconciling Itemsreconciling | segment assets | at 2024-02-29 | ¥9.5bn |
| Reconciling Itemsreconciling | segment profit | 2023-03-01 → 2024-02-29 | −¥329m |
| Dispensing Pharmacyreportable segment | capex | 2023-03-01 → 2024-02-29 | ¥265m |
| Dispensing Pharmacyreportable segment | depreciation | 2023-03-01 → 2024-02-29 | ¥174m |
| Dispensing Pharmacyreportable segment | revenue | 2023-03-01 → 2024-02-29 | ¥23.5bn |
| Dispensing Pharmacyreportable segment | revenue external | 2023-03-01 → 2024-02-29 | ¥23.5bn |
| Dispensing Pharmacyreportable segment | segment assets | at 2024-02-29 | ¥6.6bn |
| Dispensing Pharmacyreportable segment | segment profit | 2023-03-01 → 2024-02-29 | ¥1.4bn |
| Health Carereportable segment | capex | 2023-03-01 → 2024-02-29 | ¥32m |
| Health Carereportable segment | depreciation | 2023-03-01 → 2024-02-29 | ¥369m |
| Health Carereportable segment | revenue | 2023-03-01 → 2024-02-29 | ¥7.7bn |
| Health Carereportable segment | revenue external | 2023-03-01 → 2024-02-29 | ¥7.7bn |
| Health Carereportable segment | revenue intersegment | 2023-03-01 → 2024-02-29 | ¥600,000 |
| Health Carereportable segment | segment assets | at 2024-02-29 | ¥9.7bn |
| Health Carereportable segment | segment profit | 2023-03-01 → 2024-02-29 | ¥174m |
| Medical Products Wholesalereportable segment | capex | 2023-03-01 → 2024-02-29 | ¥4m |
| Medical Products Wholesalereportable segment | depreciation | 2023-03-01 → 2024-02-29 | ¥6m |
| Medical Products Wholesalereportable segment | revenue | 2023-03-01 → 2024-02-29 | ¥9.3bn |
| Medical Products Wholesalereportable segment | revenue external | 2023-03-01 → 2024-02-29 | ¥8.4bn |
| Medical Products Wholesalereportable segment | revenue intersegment | 2023-03-01 → 2024-02-29 | ¥874m |
| Medical Products Wholesalereportable segment | segment assets | at 2024-02-29 | ¥4.2bn |
| Medical Products Wholesalereportable segment | segment profit | 2023-03-01 → 2024-02-29 | ¥177m |
| Real Estatereportable segment | capex | 2023-03-01 → 2024-02-29 | ¥2m |
| Real Estatereportable segment | depreciation | 2023-03-01 → 2024-02-29 | ¥32m |
| Real Estatereportable segment | revenue | 2023-03-01 → 2024-02-29 | ¥186m |
| Real Estatereportable segment | revenue external | 2023-03-01 → 2024-02-29 | ¥181m |
| Real Estatereportable segment | revenue intersegment | 2023-03-01 → 2024-02-29 | ¥5m |
| Real Estatereportable segment | segment assets | at 2024-02-29 | ¥1.7bn |
| Real Estatereportable segment | segment profit | 2023-03-01 → 2024-02-29 | ¥132m |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-03-01 → 2024-02-29 | ¥302m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-03-01 → 2024-02-29 | ¥581m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-03-01 → 2024-02-29 | ¥40.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-03-01 → 2024-02-29 | ¥39.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-03-01 → 2024-02-29 | ¥879m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-02-29 | ¥22.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-03-01 → 2024-02-29 | ¥1.9bn |
| Dispensing Pharmacyreportable segment | employees | at 2025-02-28 | 2 pure |
| Health Carereportable segment | employees | at 2025-02-28 | 1 pure |
| Real Estatereportable segment | employees | at 2025-02-28 | 1 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,535
| Item | Context | Value | Unit |
|---|---|---|---|
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.860 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.777 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 14.3 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 20 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 70.3 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 75 | |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 1104000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E03443-000DispensingPharmacyReportableSegmentsMember | 224000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E03443-000HealthCareReportableSegmentsMember | 791000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 28000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_CorporateSharedMember | 60000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 4070000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 3770000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 4070000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 3770000 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 3 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 15 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 25 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 9 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 481 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 533 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 1287 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 224 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 24817 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 262 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 14096 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 40686 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 1400 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.0316 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0055 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.6100 | |
| Percentage of shareholdings foreigners other than individuals | CurrentYearInstant_OrdinaryShareMember | 0.0064 | |
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.3465 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 1020000 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.2711 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 710800 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.1889 | |
| Number of shares held | CurrentYearInstant_No3MajorShareholdersMember | 360000 | |
| Shareholding ratio | CurrentYearInstant_No3MajorShareholdersMember | 0.0957 | |
| Number of shares held | CurrentYearInstant_No4MajorShareholdersMember | 203000 | |
| Shareholding ratio | CurrentYearInstant_No4MajorShareholdersMember | 0.0539 | |
| Number of shares held | CurrentYearInstant_No5MajorShareholdersMember | 157834 | |
| Shareholding ratio | CurrentYearInstant_No5MajorShareholdersMember | 0.0419 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 22 of 22 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |